Literature DB >> 2227564

Chromosome abnormalities in human epithelial ovarian malignancies.

H H Gallion1, D E Powell, L W Smith, J K Morrow, A W Martin, J R van Nagell, E S Donaldson.   

Abstract

Karyotypic analysis of tumor specimens from 29 patients with untreated epithelial ovarian carcinoma was performed at the University of Kentucky Medical Center. Twenty-three of the twenty-nine tumors had adequate cells for analysis. Seventeen of these tumors exhibited chromosome abnormalities. Chromosome alterations were complex, with an average of seven different abnormal chromosomal patterns per tumor (range 2-14). Chromosomes 1 and 11 were the most commonly involved, being abnormal in 89 and 83% of tumors, respectively. Chromosomes 3 and 7 were also frequently abnormal. In contrast to invasive tumors, alterations in chromosomes 1 and 11 were not seen in the two tumors of borderline malignant potential. Evidence for DNA amplification of IGF2, Ha-ras-1, and c-ets was not observed. Amplification of the c-erbB-2 oncogene was present in two tumors. These findings indicate that multiple karyotypic abnormalities occur in untreated epithelial ovarian malignancies, with chromosomes 1 and 11 being the most frequently abnormal. These data also suggest that alterations of these chromosomes may be associated with the biologically aggressive behavior of frankly invasive ovarian tumors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2227564     DOI: 10.1016/0090-8258(90)90094-2

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

1.  Error-promoting DNA synthesis in ovarian cancer cells.

Authors:  Heqiao Dai; Robert J Hickey; Jianying Liu; Robert M Bigsby; Carita Lanner; Linda H Malkas
Journal:  Gynecol Oncol       Date:  2013-07-12       Impact factor: 5.482

2.  Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation.

Authors:  J Dent; G D Hall; N Wilkinson; T J Perren; I Richmond; A F Markham; H Murphy; S M Bell
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.